BioMarin Pharmaceuticals

BMRN

Market cap $10.7B

BioMarin Pharmaceutical Inc. ( BMRN ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST Company Participants Alexander Hardy - President, CEO & Director Brian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Day 2 of our London Healthcare Conference. Great to see everyone.

SAN RAFAEL, Calif. , Nov. 11, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England in London.

Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet alone FDA PDUFA target action date of Feb. 28, 2026 SAN RAFAEL, Calif. , Oct. 29, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the company's PALYNZIQ ® (pegvaliase-pqpz) supplemental Biologics License Application (sBLA) to expand treatment to include adolescents aged 12-17 with phenylketonuria (PKU).

The biotech published its latest set of quarterly results. It posted a surprise net profit for the period.

BMRN tops Q3 earnings expectations but misses on sales. The company moves to divest its hemophilia gene therapy, Roctavian.

Biomarin Pharmaceutical Inc (NASDAQ:BMRN) reported weaker-than-expected earnings for the third quarter on Monday.

BioMarin Pharmaceuticals shares have fallen to decade lows, reflecting investor concerns despite profitable growth and a strong net cash position. Its results showed double-digit revenue growth, but recent quarters revealed slowing sales momentum, especially for key drugs like Voxzogo and Roctavian. Competition and product setbacks cast doubt on achieving 2027 growth targets, even as the company maintains a sub-3x sales multiple and robust cash reserves.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q3 2025 Earnings Call October 27, 2025 4:30 PM EDT Company Participants Traci McCarty - Group Vice President Alexander Hardy - President, CEO & Director Brian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Philip Nadeau - TD Cowen, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Julian Pino Christopher Raymond - Raymond James & Associates, Inc., Research Division Sean Laaman - Morgan Stanley, Research Division Presentation Operator Hello, and welcome to the BioMarin Pharmaceutical Third Quarter 2025 Conference Call. [Operator Instructions].

BioMarin Pharmaceutical (Nasdaq: BMRN) missed both revenue and earnings estimates in the third quarter, and yet, shares are up 1% in after-hours trading.

The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.